Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD). [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating oral CT1812 in geographic atrophy secondary to dry age-related macular degeneration has been terminated; no efficacy or safety result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• CT1812

Snippet

Sponsor: Cognition Therapeutics | Conditions: Age-Related Macular Degeneration | Phase 2 | Status: TERMINATED